Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant

Abstract

ObjectiveTo summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment.MethodsFrom December 10, 2022, to January 20, 2023, the clinical data of children with hematological diseases diagnosed with novel coronavirus infection in the outpatient and emergency department of the Seventh Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed.ResultsAccording to whether to give paxlovid or not, it is divided into group A (paxlovid group) and group B (non-paxlovid group). The length of fever was 1–6 days in group A and 0–3 days in group B. The viral clearance time was shorter in group A than in group B. The inflammatory indexes CRP and PCT were significantly higher in group A than in group B (P < 0.05). Twenty patients were followed up for 1 month after leaving the hospital, and there were 5 cases of reappearance of fever, 1 case of increased sleep, 1 case of physical fatigue and 1 case of loss of appetite within 2 weeks.ConclusionsPaxlovid has no apparent adverse reactions in children 12 years old and younger with underlying hematological diseases infected with the new coronavirus. Focusing on the interaction between paxlovid and other drugs is necessary during the treatment.

Challenges in Treating Pediatric Cancer Patients during the COVID-19 Pandemic: Balancing Risks and Care

“…The emergency authorization also included "qualified" pediatric patients aged 12 to 18. In cohorts in which the efficacy of Paxlovid TM was evaluated in pediatric patients and in patients with oncologic conditions, the viral clearance time was significantly lower in those treated with Paxlovid TM (p = 0.033), but the levels of markers of inflammation were significantly greater (p < 0.05) [34]. On the other hand, Yan reported in his cohort that he found no significant differences in adverse effects, disease severity, or viral clearance times [35].…”

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence

“…Another study conducted by Li et al explored the clinical efficacy of Paxlovid in children with a baseline hematological malignancy who were diagnosed with a SARS-CoV-2 infection. Among the Paxlovid and non-Paxlovid cohorts, it was indicated that children who received the oral antiviral treatment demonstrated shorter times of viral clearance and no adverse reactions to treatment, but on the other hand, underwent more extended periods of fever and presented with higher inflammation markers [101].…”